中央神经系统中存在争议的高风险扩散型大B细胞淋巴瘤的预防
Sabela Bobillo1, Matthew R Wilson2, Kate Cwynarski3
1Department of Haematology, Vall d'Hebron Institute of Oncology, University Hospital Vall d'Hebron, Barcelona, Spain.
Current opinion in oncology
|August 8, 2023
概括
在扩散性大B细胞淋巴瘤 (DLBCL) 中,中枢神经系统 (CNS) 复发是罕见但严重的. 像ctDNA分析这样的新方法可以改善识别高风险患者,以更好地预防中枢神经系统.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 神经学 神经学
背景情况:
- 扩散型大B细胞淋巴瘤 (DLBCL) 中的中枢神经系统 (CNS) 复发是一种罕见但严重的并发症,预后不佳.
- 鉴定中枢神经系统复发的高风险患者对于有效的预防策略至关重要.
结论:
- 在DLBCL中,中枢神经系统复发的风险分层正在通过新的生物标志物得到改善.
- 高风险DLBCL患者的最佳中枢神经系统预防策略需要进一步调查.
- 正在探索新的治疗方法,以加强中枢神经系统复发的预防.
更多相关视频
相关概念视频
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Drug Delivery: Parenteral Route
618
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
618


